+
データを開く
-
基本情報
| 登録情報 | データベース: EMDB / ID: EMD-22016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| タイトル | Wt pig RyR1 in complex with apoCaM, EGTA condition (class 3, open) | |||||||||
マップデータ | RyR1, FKBP12.6, CaM | |||||||||
試料 |
| |||||||||
キーワード | receptor / calcium / channel / complex / TRANSPORT PROTEIN-ISOMERASE-CALCIUM BINDING PROTEIN complex | |||||||||
| 機能・相同性 | 機能・相同性情報positive regulation of sequestering of calcium ion / negative regulation of calcium-mediated signaling / negative regulation of insulin secretion involved in cellular response to glucose stimulus / neuronal action potential propagation / negative regulation of release of sequestered calcium ion into cytosol / insulin secretion involved in cellular response to glucose stimulus / CaM pathway / Cam-PDE 1 activation / Sodium/Calcium exchangers / response to redox state ...positive regulation of sequestering of calcium ion / negative regulation of calcium-mediated signaling / negative regulation of insulin secretion involved in cellular response to glucose stimulus / neuronal action potential propagation / negative regulation of release of sequestered calcium ion into cytosol / insulin secretion involved in cellular response to glucose stimulus / CaM pathway / Cam-PDE 1 activation / Sodium/Calcium exchangers / response to redox state / Calmodulin induced events / Reduction of cytosolic Ca++ levels / Activation of Ca-permeable Kainate Receptor / CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde / Loss of phosphorylation of MECP2 at T308 / negative regulation of heart rate / 'de novo' protein folding / CREB1 phosphorylation through the activation of Adenylate Cyclase / negative regulation of high voltage-gated calcium channel activity / PKA activation / CaMK IV-mediated phosphorylation of CREB / Glycogen breakdown (glycogenolysis) / CLEC7A (Dectin-1) induces NFAT activation / Activation of RAC1 downstream of NMDARs / negative regulation of ryanodine-sensitive calcium-release channel activity / organelle localization by membrane tethering / mitochondrion-endoplasmic reticulum membrane tethering / autophagosome membrane docking / FK506 binding / negative regulation of calcium ion export across plasma membrane / regulation of cardiac muscle cell action potential / presynaptic endocytosis / Synthesis of IP3 and IP4 in the cytosol / regulation of cell communication by electrical coupling involved in cardiac conduction / Phase 0 - rapid depolarisation / calcineurin-mediated signaling / Negative regulation of NMDA receptor-mediated neuronal transmission / Unblocking of NMDA receptors, glutamate binding and activation / RHO GTPases activate PAKs / Ion transport by P-type ATPases / Uptake and function of anthrax toxins / regulation of ryanodine-sensitive calcium-release channel activity / Long-term potentiation / protein phosphatase activator activity / smooth muscle contraction / Calcineurin activates NFAT / Regulation of MECP2 expression and activity / DARPP-32 events / Smooth Muscle Contraction / detection of calcium ion / regulation of cardiac muscle contraction / catalytic complex / RHO GTPases activate IQGAPs / T cell proliferation / regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion / calcium channel inhibitor activity / cellular response to interferon-beta / Activation of AMPK downstream of NMDARs / presynaptic cytosol / Protein methylation / regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum / eNOS activation / Ion homeostasis / titin binding / Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation / regulation of calcium-mediated signaling / sperm midpiece / release of sequestered calcium ion into cytosol / voltage-gated potassium channel complex / FCERI mediated Ca+2 mobilization / calcium channel complex / substantia nigra development / sarcoplasmic reticulum membrane / regulation of heart rate / FCGR3A-mediated IL10 synthesis / Ras activation upon Ca2+ influx through NMDA receptor / Antigen activates B Cell Receptor (BCR) leading to generation of second messengers / calyx of Held / adenylate cyclase activator activity / protein maturation / sarcomere / VEGFR2 mediated cell proliferation / protein serine/threonine kinase activator activity / VEGFR2 mediated vascular permeability / regulation of cytokinesis / spindle microtubule / positive regulation of receptor signaling pathway via JAK-STAT / Translocation of SLC2A4 (GLUT4) to the plasma membrane / calcium channel regulator activity / peptidylprolyl isomerase / peptidyl-prolyl cis-trans isomerase activity / calcium-mediated signaling / RAF activation / Transcriptional activation of mitochondrial biogenesis / response to calcium ion / cellular response to type II interferon / G2/M transition of mitotic cell cycle / Stimuli-sensing channels / Z disc / long-term synaptic potentiation 類似検索 - 分子機能 | |||||||||
| 生物種 | ![]() Homo sapiens (ヒト) | |||||||||
| 手法 | 単粒子再構成法 / クライオ電子顕微鏡法 / 解像度: 4.2 Å | |||||||||
データ登録者 | Woll KW / Haji-Ghassemi O | |||||||||
| 資金援助 | 1件
| |||||||||
引用 | ジャーナル: Nat Commun / 年: 2021タイトル: Pathological conformations of disease mutant Ryanodine Receptors revealed by cryo-EM. 著者: Kellie A Woll / Omid Haji-Ghassemi / Filip Van Petegem / ![]() 要旨: Ryanodine Receptors (RyRs) are massive channels that release Ca from the endoplasmic and sarcoplasmic reticulum. Hundreds of mutations are linked to malignant hyperthermia (MH), myopathies, and ...Ryanodine Receptors (RyRs) are massive channels that release Ca from the endoplasmic and sarcoplasmic reticulum. Hundreds of mutations are linked to malignant hyperthermia (MH), myopathies, and arrhythmias. Here, we explore the first MH mutation identified in humans by providing cryo-EM snapshots of the pig homolog, R615C, showing that it affects an interface between three solenoid regions. We also show the impact of apo-calmodulin (apoCaM) and how it can induce opening by bending of the bridging solenoid, mediated by its N-terminal lobe. For R615C RyR1, apoCaM binding abolishes a pathological 'intermediate' conformation, distributing the population to a mixture of open and closed channels, both different from the structure without apoCaM. Comparisons show that the mutation primarily affects the closed state, inducing partial movements linked to channel activation. This shows that disease mutations can cause distinct pathological conformations of the RyR and facilitate channel opening by disrupting interactions between different solenoid regions. | |||||||||
| 履歴 |
|
-
構造の表示
| ムービー |
ムービービューア |
|---|---|
| 構造ビューア | EMマップ: SurfView Molmil Jmol/JSmol |
| 添付画像 |
-
ダウンロードとリンク
-EMDBアーカイブ
| マップデータ | emd_22016.map.gz | 57.4 MB | EMDBマップデータ形式 | |
|---|---|---|---|---|
| ヘッダ (付随情報) | emd-22016-v30.xml emd-22016.xml | 18.6 KB 18.6 KB | 表示 表示 | EMDBヘッダ |
| 画像 | emd_22016.png | 209.7 KB | ||
| Filedesc metadata | emd-22016.cif.gz | 7.9 KB | ||
| アーカイブディレクトリ | http://ftp.pdbj.org/pub/emdb/structures/EMD-22016 ftp://ftp.pdbj.org/pub/emdb/structures/EMD-22016 | HTTPS FTP |
-検証レポート
| 文書・要旨 | emd_22016_validation.pdf.gz | 457.6 KB | 表示 | EMDB検証レポート |
|---|---|---|---|---|
| 文書・詳細版 | emd_22016_full_validation.pdf.gz | 457.1 KB | 表示 | |
| XML形式データ | emd_22016_validation.xml.gz | 7.7 KB | 表示 | |
| CIF形式データ | emd_22016_validation.cif.gz | 8.9 KB | 表示 | |
| アーカイブディレクトリ | https://ftp.pdbj.org/pub/emdb/validation_reports/EMD-22016 ftp://ftp.pdbj.org/pub/emdb/validation_reports/EMD-22016 | HTTPS FTP |
-関連構造データ
-
リンク
| EMDBのページ | EMDB (EBI/PDBe) / EMDataResource |
|---|---|
| 「今月の分子」の関連する項目 |
-
マップ
| ファイル | ダウンロード / ファイル: emd_22016.map.gz / 形式: CCP4 / 大きさ: 421.9 MB / タイプ: IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 注釈 | RyR1, FKBP12.6, CaM | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 投影像・断面図 | 画像のコントロール
画像は Spider により作成 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ボクセルのサイズ | X=Y=Z: 1.09 Å | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 密度 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 対称性 | 空間群: 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 詳細 | EMDB XML:
CCP4マップ ヘッダ情報:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-添付データ
-
試料の構成要素
-全体 : ryanodine receptor-FKBP1B-Calmodulin complex
| 全体 | 名称: ryanodine receptor-FKBP1B-Calmodulin complex |
|---|---|
| 要素 |
|
-超分子 #1: ryanodine receptor-FKBP1B-Calmodulin complex
| 超分子 | 名称: ryanodine receptor-FKBP1B-Calmodulin complex / タイプ: complex / ID: 1 / 親要素: 0 / 含まれる分子: #1-#3 |
|---|
-超分子 #2: ryanodine receptor
| 超分子 | 名称: ryanodine receptor / タイプ: complex / ID: 2 / 親要素: 1 / 含まれる分子: #2 |
|---|---|
| 由来(天然) | 生物種: ![]() |
-超分子 #3: FKBP1B
| 超分子 | 名称: FKBP1B / タイプ: complex / ID: 3 / 親要素: 1 / 含まれる分子: #1 |
|---|---|
| 由来(天然) | 生物種: Homo sapiens (ヒト) |
-超分子 #4: Calmodulin
| 超分子 | 名称: Calmodulin / タイプ: complex / ID: 4 / 親要素: 1 / 含まれる分子: #3 |
|---|---|
| 由来(天然) | 生物種: Homo sapiens (ヒト) |
-分子 #1: Peptidyl-prolyl cis-trans isomerase FKBP1B
| 分子 | 名称: Peptidyl-prolyl cis-trans isomerase FKBP1B / タイプ: protein_or_peptide / ID: 1 / コピー数: 4 / 光学異性体: LEVO / EC番号: peptidylprolyl isomerase |
|---|---|
| 由来(天然) | 生物種: Homo sapiens (ヒト) |
| 分子量 | 理論値: 11.667305 KDa |
| 組換発現 | 生物種: ![]() |
| 配列 | 文字列: GVEIETISPG DGRTFPKKGQ TCVVHYTGML QNGKKFDSSR DRNKPFKFRI GKQEVIKGFE EGAAQMSLGQ RAKLTCTPDV AYGATGHPG VIPPNATLIF DVELLNLE UniProtKB: Peptidyl-prolyl cis-trans isomerase FKBP1B |
-分子 #2: Ryanodine Receptor
| 分子 | 名称: Ryanodine Receptor / タイプ: protein_or_peptide / ID: 2 / コピー数: 4 / 光学異性体: LEVO |
|---|---|
| 由来(天然) | 生物種: ![]() |
| 分子量 | 理論値: 425.09225 KDa |
| 配列 | 文字列: QFLRTDDEVV LQCNATVLKE QLKLCLAAEG FGNRLCFLEP TSNAQNVPPD LAICCFVLEQ SLSVRALQEM LANGHRTLLY GHAILLRHA HSGMYLSCLT TSRSMTDKLA FDVGLQEDAT GEACWWTTHP ASKQRSEGEK VRVGDDLILV SVSSERYLHL S TASGELQV ...文字列: QFLRTDDEVV LQCNATVLKE QLKLCLAAEG FGNRLCFLEP TSNAQNVPPD LAICCFVLEQ SLSVRALQEM LANGHRTLLY GHAILLRHA HSGMYLSCLT TSRSMTDKLA FDVGLQEDAT GEACWWTTHP ASKQRSEGEK VRVGDDLILV SVSSERYLHL S TASGELQV DASFMQTLWN MNPICSGCEE GYVTGGHVLR LFHGHMDECL TISPADSDDQ RRLVYYEGGS VCTHARSLWR LE PLRISWS GSHLRWGQPL RIRHVTTGRY LALIEDQGLV VVDASKAHTK ATSFCFRISK EKLKRDVEGM GPPEIKYGES LCF VQHVAS GLWLTYAALK KKAILHQEGH MDDALSLTRC QQEESQAARM IYSTAGLYNH FIKGLDSFSG KPRGSGAPAG TALP LEGVI LSLQDLIGYF EPPSEELQHE EKQSKLRSLR NRQSLFQEEG MLSLVLNCID RLNVYTTAAH FAEFAGEEAA ESWKE IVNL LYEILASLIR GNRANCALFS NNLDWLVSKL DRLEASSGIL EVLYCVLIES PEVLNIIQEN HIKSIISLLD KHGRNH KVL DVLCSLCVCN GVAVRSNQDL ITENLLPGRE LLLQTNLINY VTSIRPNIFV GRAEGTTQYS KWYFEVMVDE VVPFLTA QA THLRVGWALT EGYSPYPGGG EGWGGNGVGD DLYSYGFDGL HLWTGHVPRL VTSPGQHLLA PEDVVSCCLD LSVPSISF R INGCPVQGVF EAFNLNGLFF PVVSFSAGVK VRFLLGGRHG EFKFLPPPGY APCHEAVLPR ERLRLEPIKE YRREGPRGP HLVGPSRCLS HTDFVPCHLE RIREKLAENI HELWALTRIE QGWTYGPVRD DNKRLHPCLV DFHSLPEPER NYNLQMSGET LKTLLALGC HVGMADEKAE DNLRKTKLPK TYMMSNGYKP APLDLSHVRL TPAQTTLVDR LAENGHNVWA RDRVAQGWSY S AVQDIPAR RNPRLVPYRL LDEATKRSNR DSLCQAVRTL LGYGYNIERV RIFRAEKSYA VQSGRWYFEF EAVTTGEMRV GW ARPELRP DVELGADELA YVFNGHRGQR WHLGSELFGR PWQSGDVVGC MIDLTENTII FTLNGEVLMS DSGSETAFRD IEV GDGFLP VCSLGPGQVG HLNLGQDVSS LRFFAICGLQ EGFEPFAINM QRPVTTWFSK SLPQFEAVPL EHPHYEVSRV DGTV DTPPC LRLTHRSLVE MLFLRLSLPV QFHQLNTTTY YYSVRVFAGQ EPSCVWVGWV TPDYHQHDMN FDLTKVRAVT VTMGD NIHS SLKCSNCYMV WGGDFVSHTD LVIGCLVDLA TGLMTFTANG KESNTFFQVE PNTKLFPAVF VLPTHQNVIQ FELGKQ KNI MPLSAAMFLS ERKNPAPQCP PRLEMQMLMP VSWSRMPNHF LRVETRRAGE RLGWAVQCQE PLTMMALHIP EENRCMD IL ELSERLDLQQ FHSHTLRLYR AVCALGNNRV AHALCSHVDQ AQLLHALEDA HLPGPLRAGY YDLLISIHLE SACRSRRS M LSEYIVPLTP ETRAITLFPP RHGLPGVGVT TSLRPPHHFS APCFVAALPE APARLSPSIP LEALRDKALR MLGEAVRDG GQHARDPVGG SVEFQFVPVL KLVSTLLVMG IFGDEDVKQI LKMIEPEVEE GLLQMKLPES VKLQMCNLLE YFCDQELQHR VESLAAFAE RYVDKLQANQ RDRYGILMKA FTMTAAETAR RTREFRSPPQ EQINMLLHFK PLPDEIRQDL LEFHQDLLTH C GIQLQSLQ ELVSHTVVRW AQEDFVQSPE LVRAMFSLLH RQYDGLGELL RALPRAYTIS PSSVEDTMSL LECLGQIRSL LI VQMGPQE ENLMIQSIGN IMNNKVFYQH PNLMRALGMH ETVMEVMVNV LRFPKMVTSC CRFLCYFCRI SRQNQRSMFD HLS YLLENS GGMQGSTPLD VAAASVIDNN ELALALQEQD LEKVVSYLAG CGLQSCPMLL AKGYPDIGWN PCGGERYLDF LRFA VFVNG ESVEENANVV VRLLIRKPEC FGPALRGEGG SGLLATIEEA IHLGHAIMSF YAALIDLLGR CAPEMHLIQA GKGEA LRIR AILRSLVPLD DLVGIISLPL QIPMSASFVP DHKASMVLFL DRVYGIENQD FLLHVLDVGF LPDMRAAALA LNRYLC LAV LPLITKCAPL FAMVDSMLHT VYRLSRGRSL TKAQRDVIEE CLMALCRYIR PSMLQHLLRR LVF(UNK)(UNK) (UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)DPRPVETL NVIIPEKLDS FI NKFAEYT HEKWAFDKIQ NNWSYGENID EELKTHPMLR PYKTFSEKDK EIYRWPIKES LKAMIAWEWT IEKAREGEYN PQP PDLSGV TLSRELQAMA EQLAENYHNT WGRKKKQELE AKGGGTHPLL VPYDTLTAKE KARDREKAQE LLKFLQMNGY AVTR (UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)F SVLCRDLYAL YPLL IRYVD NNRAHWLTEP NPSAEELFRM VGEIFIYWSK SHNFKREEQN FVV(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)HKLLS KQRRR AVVA CFRMTPLYNL PTHRACNMFL ESYKAAWILT EDHSFEDRMI DDLSKAGEQE EEEEEVEEKK PDPLHQLVLH FSRTAL TEK SKLDEDYLYM AYADIMAKSC HLEESFEEKE MEKQRLLYQQ ARLHNRGAAE MVLQMISACK GETGAMVSST LKLGISI LN GGNADVQQKM LDYLKDKKEV GFFQSIQALM QTCSVLDLNA FERQNKAEGL GMVNEDGTVI GEKVMADDEF TQDLFRFL Q LLCEGHNNDF QNYLRTQTGN TTTINIIICT VDYLLRLQES ISDFYWYYSG KDVIEEQGKR NFSKAMSVAK QVFNSLTEY IQGPCTGNQQ SLAHSRLWDA VVGFLHVFAH MMMKLAQDSS QIELLKELLD LQKDMVVMLL SLLEGNVVNG MIARQMVDML VESSSNVEM ILKFFDMFLK LKDIVGSEAF QDYVTDPRGL ISKKDFQK(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)EFA NR FQEPARDIGF NVAVLLTNLS EHVPHDPRLR NFLELAESIL EYFRPYLGRI EIMGASRRIE RIYFEISETN RAQWEMPQ V KESKRQFIFD VVNEKMELFV SFCEDTIFEM QIAAQ(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK) (UNK)(UNK)(UNK)(UNK)(UNK)(UNK) (UNK)(UNK)(UNK)EVQRVKF LNYLSRNFYT LRFLALFLAF AINFILLF Y KVSDSPPVYY FLEESTGYME PALRCLSLLH TLVAFLCIIG YNCLKVPLVI FKREKELARK LEFDGLYITE QPEDDDVKG QWDRLVLNTP SFPSNYWDKF VKRKVLDKHG DIYGRERIAE IDVKYQIWKF GVIFTDNSFL YLGWYMVMSL LGHYNNFFFA AHLLDIAMG VKTLRTILSS VTHNGKQLVM TVGLLAVVVY LYTVVAFNFF RKFYNKMKCD DMMTCYLFHM YVGVRAGGGI G DEIEDPAG DEYELYRVVF DITFFFFVIV ILLAIIQGLI IDAFGELRDQ QEQVREDMET KCFICGIGSD YFDTTPHRFE TH TLEEHNL ANYMFFLMYL INKDETEHTG QESYVWKMYQ ERCWDFFPAG DCFRKQYEDQ L |
-分子 #3: Calmodulin-1
| 分子 | 名称: Calmodulin-1 / タイプ: protein_or_peptide / ID: 3 / コピー数: 4 / 光学異性体: LEVO |
|---|---|
| 由来(天然) | 生物種: Homo sapiens (ヒト) |
| 分子量 | 理論値: 16.723365 KDa |
| 組換発現 | 生物種: ![]() |
| 配列 | 文字列: MADQLTEEQI AEFKEAFSLF DKDGDGTITT KELGTVMRSL GQNPTEAELQ DMINEVDADG NGTIDFPEFL TMMARKMKDT DSEEEIREA FRVFDKDGNG YISAAELRHV MTNLGEKLTD EEVDEMIREA DIDGDGQVNY EEFVQMMTA UniProtKB: Calmodulin-1 |
-分子 #4: ZINC ION
| 分子 | 名称: ZINC ION / タイプ: ligand / ID: 4 / コピー数: 4 / 式: ZN |
|---|---|
| 分子量 | 理論値: 65.409 Da |
-実験情報
-構造解析
| 手法 | クライオ電子顕微鏡法 |
|---|---|
解析 | 単粒子再構成法 |
| 試料の集合状態 | particle |
-
試料調製
| 緩衝液 | pH: 7.5 |
|---|---|
| グリッド | 詳細: unspecified |
| 凍結 | 凍結剤: ETHANE |
-
電子顕微鏡法
| 顕微鏡 | FEI TITAN KRIOS |
|---|---|
| 撮影 | フィルム・検出器のモデル: FEI FALCON III (4k x 4k) 平均電子線量: 50.0 e/Å2 |
| 電子線 | 加速電圧: 300 kV / 電子線源: FIELD EMISSION GUN |
| 電子光学系 | 照射モード: OTHER / 撮影モード: DIFFRACTION |
| 実験機器 | ![]() モデル: Titan Krios / 画像提供: FEI Company |
-
画像解析
| 初期モデル | モデルのタイプ: PDB ENTRY |
|---|---|
| 最終 再構成 | 解像度のタイプ: BY AUTHOR / 解像度: 4.2 Å / 解像度の算出法: FSC 0.143 CUT-OFF / ソフトウェア - 名称: PHENIX (ver. dev-3714) / 使用した粒子像数: 25122 |
| 初期 角度割当 | タイプ: MAXIMUM LIKELIHOOD |
| 最終 角度割当 | タイプ: MAXIMUM LIKELIHOOD |
ムービー
コントローラー
万見について



キーワード
Homo sapiens (ヒト)
データ登録者
引用
UCSF Chimera






































Z (Sec.)
Y (Row.)
X (Col.)























